Related Experiment Video
Updated: Oct 16, 2025
06:35
Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
Published on: April 27, 2016
17.9K
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
Teresa Salvatore1, Alfredo Caturano2, Raffaele Galiero2
1Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via De Crecchio 7, I-80138 Naples, Italy.
Biomedicines
|October 23, 2021
Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, used for type 2 diabetes mellitus (T2DM), show cardiovascular benefits by improving endothelial function and reducing atherosclerotic cardiovascular disease (CVD) risk.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) significantly increases the risk of atherosclerotic cardiovascular disease (CVD), particularly heart failure (HF).
- Endothelial dysfunction (ED) is an early indicator of atherosclerosis and a key contributor to diabetic complications, affecting both macrovascular and microvascular health.
- Managing cardiovascular outcomes is as critical as glycemic control in T2DM patients.
Purpose of the Study:
- To review the cardiovascular protective mechanisms of SGLT2 inhibitors in T2DM patients.
- To analyze the impact of SGLT2 inhibition on endothelial function.
- To elucidate the underlying pathophysiology of SGLT2 inhibitors' cardiovascular benefits.
Main Methods:
- Literature review of studies investigating SGLT2 inhibitors and cardiovascular outcomes.
- Analysis of research on endothelial dysfunction in T2DM.
- Examination of the molecular and cellular mechanisms of SGLT2 inhibition.
Main Results:
- SGLT2 inhibitors demonstrate significant cardiovascular protective effects in T2DM.
- These agents appear to improve endothelial function, counteracting ED.
- Potential mechanisms include reduced inflammation, oxidative stress, and improved vascular tone.
Conclusions:
- SGLT2 inhibition offers a promising therapeutic strategy for reducing cardiovascular risk in T2DM.
- Improving endothelial function is a key pathway through which SGLT2 inhibitors exert their cardioprotective effects.
- Further research is needed to fully understand the multifaceted benefits of SGLT2 inhibitors in diabetic cardiovascular disease.
More Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
340
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
340
01:23Dipeptidyl Peptidase 4 Inhibitors
292
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
292
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
317
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
317
01:06Oral Hypoglycemic Agents: Glinides
304
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
304
01:24Glucagon-like Receptor Agonists
476
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
476
01:16Hormones Regulating Blood Glucose
4.8K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.8K